Business Trends– category –
-
ASE to Commence FOPLP Mass Production by End-2026, Launching 15 Expansion Projects Amid AI Chip Boom
TrendForce Taiwan Overview ASE Technology, the world's largest semiconductor packaging and testing services provider, announced plans to begin mass production of Fan-out Panel-Level Packaging (FOPLP) by the end of 2026. This initiative, ... -
UBC-Led Global Review Reaffirms mRNA Vaccine Safety & Efficacy, Accelerating Applications in Cancer and Beyond
UBC News - The University of British Columbia Canada Overview An extensive global review led by researchers at the University of British Columbia has unequivocally reaffirmed the safety and efficacy of COVID-19 mRNA vaccines. Based on bi... -
Lonza Significantly Boosts ADC Manufacturing Capacity at Swiss Visp Site, Expanding Payload-Linker Production and Launching New Commercial Facility by 2028
Fierce Pharma Switzerland Overview Lonza announced a significant expansion of its ADC manufacturing capacity, extending a partnership with a major US drugmaker to meet the growing demand in the antibody-drug conjugate market. At its Visp... -
92Bio Doses First Patient in Phase 1 Trial of FOLR1×CD3 Bispecific T-Cell Engager NTB-928 for Platinum-Resistant Ovarian Cancer
BioPharm International USA Overview 92Bio has dosed the first patient in its Phase 1 clinical trial of NTB-928, a FOLR1×CD3 bispecific T-cell engager for platinum-resistant ovarian cancer. NTB-928 is designed to specifically kill ovarian... -
FDA Approves, Clears Trials for Autism-Related Symptom Treatments: DeFloria’s AJA001 Oral Liquid Enters Phase 2, Generic Leucovorin Approved
Barchart.com (via DelveInsight) USA Overview The FDA has authorized Phase II clinical trials for DeFloria's AJA001 oral liquid, a plant-derived drug candidate for autism spectrum disorder (ASD)-related symptoms. Additionally, in March 20... -
Exponential Progression of Targeted Protein Degradation: First FDA-Approved PROTAC and Molecular Glues Unlock “Undruggable” Targets
MarinBio (Appears to be a scientific review/journal, affiliated with MarinBio, hence using their domain) USA Overview The field of targeted protein degradation (TPD) is rapidly evolving, enabling the degradation of previously "undruggabl... -
Engineered Antibody Brainshuttle™ Technology Boosts Brain Drug Delivery of RNA-Based ASOs by Dual-Targeting TfR1 and CD98hc Receptors, Illuminating CNS Disease Treatment
EMJ Unknown Overview Antibody-based Brainshuttle™ technology has made significant strides in brain drug delivery for promising therapeutics like RNA-based antisense oligonucleotides (ASOs), which are otherwise unable to cross the blood-b... -
Ionis Enters Global Licensing Deal with Recordati for Alexander Disease ASO Zilganersen: Secures $30M Upfront Payment to Accelerate International Expansion
Rare Disease Report USA Overview Ionis Pharmaceuticals has entered a global licensing agreement with Recordati for zilganersen, an antisense oligonucleotide (ASO) for Alexander disease, covering territories outside the U.S. Ionis will re... -
Asahi Kasei’s Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar API Manufacturing Facility to Reduce Pharmaceutical Manufacturing Time for Thermolabile Peptides and Oligonucleotides, Advancing Towards GMP Production
Asahi Kasei Japan Overview Asahi Kasei has implemented a novel forward osmosis–membrane distillation (FO-MD) system at Peptistar's API manufacturing facility to shorten production times for thermolabile APIs like peptides and oligonucleo... -
Focused Ultrasound BBB Opening Facilitates Limited LNP-modRNA Brain Delivery in Niemann-Pick Disease Type C Mouse Model but Fails to Induce Therapeutic Effect
bioRxiv Unknown Overview Efficient molecular therapeutic delivery to the central nervous system (CNS) remains a major barrier in neurogenetic disorders like Niemann-Pick Disease Type C (NPC). This preprint evaluated Focused ultrasound-me...
